Compare MGM Resorts International (MGM) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs BIO-TECHNE Corp — how do they compare? MGM Resorts International trades at $29.3 (market cap $7.55B), while BIO-TECHNE Corp trades at $72.45 (market cap $11.36B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals — on Pluang, investors hold MGM Resorts International for 91 Days and BIO-TECHNE Corp for 64 Days on average.
| MGM | TECH | |
|---|---|---|
Market Cap | $7.55B | $11.36B |
Volume | 5,342,346 | 5,390,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $72.61 |
52-Week Low | $30.00 | $43.31 |
Typical Hold Time | 91 Days | 64 Days |
Enterprise Value | $34.85B | $11.39B |
Dividend Yield | 0.03% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $29.77, down 0.77% for the day amid a bearish technical signal and recent deal uncertainty. The stock has faced pressure after Barry Diller's People Inc. withdrew its $48.30 per share acquisition proposal in September 2026, contributing to a 17% decline year-to-date. Fundamentally, revenue grew to $17.54 billion in 2025, but net income margin compressed to 2.4%, while valuation metrics like a P/E of 18.19 and P/S of 0.45 suggest moderate pricing relative to sales. Analyst consensus remains bullish with a $48.75 price target, but technical indicators show selling pressure with key support at $29.
The outlook for MGM hinges on earnings execution and strategic moves, with Q3 2026 results due October 28 offering a near-term catalyst. Risks include volatile cash flows, high debt levels, and integration challenges from potential M&A. The stock's current discount to analyst targets presents opportunity if operational improvements materialize, but investors face headwinds from competitive pressures and macroeconomic sensitivity.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
